Barclays raised the firm’s price target on National Vision (EYE) to $30 from $28 and keeps an Overweight rating on the shares following the investor day. The company reiterated fiscal 2025 guidance and provided long-term targets, the analyst tells investors in a research note. The firm remains “strongly positive” on National Vision’s transformative efforts.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYE:
- Strategic Growth and Market Expansion Drive Buy Rating for National Vision Holdings
- National Vision Holdings: Strategic Growth Initiatives and Expansion Plans Drive Buy Rating
- Midday Fly By: Berkshire takes Alphabet stake, J&J buying cancer drug maker
- National Vision announces transformation strategy
- National Vision sees FY26 revenue growth in high-single digits